Author:
Beyar-Katz Ofrat,Rowe Jacob M.
Publisher
Ferrata Storti Foundation (Haematologica)
Reference5 articles.
1. Oh BLZ, Vinanica N, Wong DMH, Campana D. Chimeric antigen receptor-directed T-cell therapy for T-cell acute lymphoblastic leukemia. Haematologica. 2024; 109(6):1677-1688.
2. Hill LC, Rouce RH, Wu M. Anti-tumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024; 143(13):1231-1241.
3. Lu P, Liu Y, Yang J. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022; 140(4):321-334.
4. Ruella M, Xu J, Barrett DM. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503.
5. Pan J, Tan Y, Wang G. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021; 39(30):3340-3351.